CeloNova recently announced positive interim results from its randomized trial of Cobra PzF stenting to reduce the duration of triple therapy. The randomized, global 14-day dual anti-platelet therapy study of high bleeding risk (HBR) patients enrolled 996 HBR participants across 59 enrolling global sites. Each patient received either the Cobra … [Read more...] about CeloNova touts nano-coated stent trial results
